Panapres

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panapres

Quick Facts

Property Description
Active ingredient Atenolol
Form Oral Tablet, Injection Solution
Pharmacological class Selective beta1-Adrenergic Receptor Antagonist (Beta-blocker)
General purpose Reducing cardiac strain and lowering blood pressure
Origin Synthetic chemical compound

What is Panapres and What is Its Active Ingredient?

Panapres is a commercial pharmaceutical preparation containing the single well-established active substance, Atenolol. This medication is classified as a synthetic, chemical entity and is not derived from natural sources. Panapres is characteristically available as an oral tablet and, for more controlled settings, as a solution for intravenous injection. As a prescription-only product, its use is guided by a healthcare professional, a status that reflects its robust pharmacological profile. The formulation distinguishes itself from combination products by focusing solely on Atenolol's therapeutic effects.

Panapres: Classification as a Selective Beta-Blocker

Panapres belongs to the authoritative pharmacological class of Beta-blockers, which are scientifically identified as beta-Adrenergic Receptor Antagonists. The specific active component, Atenolol, is widely recognized as a second-generation Selective beta1-adrenergic receptor antagonist. This selectivity means the drug primarily targets the beta1-receptors found in the heart, qualifying it as a cardioselective agent. This targeted action is a key differentiating feature from older, non-selective beta-blockers.

What is the General Purpose of This Type of Medicine?

The core purpose of Panapres is to manage the physiological demands on the cardiovascular system, making it suitable for situations where reducing heart rate and force is beneficial. The medication decreases the heart rate and simultaneously reduces the force of the heart’s contractions, thereby easing cardiac workload. For instance, a typical use scenario involves helping patients whose cardiovascular system benefits from a controlled, slower rhythm. This effect is clinically recognized as contributing to the general therapeutic goals of reducing overall cardiac strain and managing blood pressure.

What side effects are possible with Panapres?

Panapres, which contains the active ingredient pantoprazole, is generally well-tolerated. However, like all medications, it can cause side effects. Most commonly reported adverse reactions are generally mild.

Common Side Effects

These side effects occur in a small percentage of patients and may include:

  • Headache
  • Gastrointestinal issues: Diarrhea, abdominal pain, nausea, vomiting, or flatulence (gas)
  • Dizziness
  • Joint pain (arthralgia)

These common side effects are often temporary and may resolve as the body adjusts to the medication.


Long-Term and Serious Safety Information

While rare, Panapres is associated with several serious or long-term risks, especially with prolonged use (typically over one year or at high doses). Patients should be monitored for these effects:

  • Bone Fracture Risk: Increased risk of fractures of the hip, wrist, or spine, particularly in older adults.
  • Nutrient Deficiencies: Prolonged use may lead to reduced absorption of certain nutrients, notably Vitamin B12 and magnesium (hypomagnesemia).
  • Kidney Problems: Rare cases of acute interstitial nephritis (sudden kidney inflammation) have been reported.
  • Gastrointestinal Infections: An increased risk of Clostridioides difficile-associated diarrhea.
  • Lupus Erythematosus: New onset or exacerbation of cutaneous (skin) or systemic lupus erythematosus.

Patients should seek immediate medical attention if they experience signs of a serious allergic reaction (e.g., swelling of the face, throat, or tongue; severe rash; or trouble breathing) or symptoms of severe liver or kidney problems.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

This section describes the officially documented manifestations and required emergency actions for Panapres (Atenolol) overdose, strictly according to regulatory prescribing information.

Overdose Manifestations Severe Outcomes Required Emergency Action
Cardiovascular: Severe bradycardia, hypotension, sinus pause, congestive heart failure. Severe: Heart block (second or third degree), cardiogenic shock, potential death with massive acute doses. Seek immediate medical attention for suspected overdose.
Systemic: Lethargy, confusion, hypoglycemia, bronchospasm. Toxicity Management: Requires continuous monitoring and symptomatic support. Contact emergency services for collapse, breathing trouble, or seizure.

Official Overdose Management Statements

The official prescribing information states that no specific antidote is known for Panapres overdose. Treatment is strictly symptomatic and supportive, using agents like Glucagon or Atropine to manage the acute physiological effects.

Management procedures documented in regulatory sources include using activated charcoal to remove unabsorbed drug and noting that hemodialysis can remove Atenolol from systemic circulation. Due to drug elimination via the kidneys, patients with severe renal impairment may have a prolonged risk of toxicity. Continuous monitoring in a hospital setting is required for cardiovascular stability.

Therapeutic Uses of Panapres

What Panapres Treats: Main Uses and Benefits

Panapres is commonly used in conditions presenting with symptomatic burden related to the cardiovascular system. It is applied across therapeutic domains where additional symptomatic support is generally needed to promote stability. This medication is primarily relevant for managing conditions including: Hypertension (high blood pressure), Angina Pectoris (recurrent chest pain), and is used in settings marked by temporary physiological imbalance following a Myocardial Infarction (heart attack).

This medication is also relevant for easing symptom clusters that create noticeable physiological strain, such as rapid or irregular heart rhythms and certain episodic manifestations like migraines.

“This medication offers symptomatic relief that helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases.”

By helping to manage systemic imbalance in chronic conditions like Hypertension, it may assist with maintaining functional stability. For acute symptomatic episodes like Angina, it contributes to easing the overall symptom load.


Quick Fact: Relief for Cardiovascular Strain

Symptom Type Condition Category Primary Benefit
Elevated Arterial Pressure Conditions with Systemic Stress Supports general well-being
Recurrent Chest Pain (Angina) Conditions with Episodic Manifestations Assists with easing symptom load
Rapid Heart Rate (Tachycardia) Conditions with Heightened Activity Contributes to steady coping

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Panapres? (Atenolol)

Official regulatory information strictly defines the population groups eligible for Panapres use, establishing absolute non-eligibility for certain conditions and restrictions for others.

Contraindicated Populations (Must Not Use)

Panapres is formally contraindicated and must not be used in patients with specific, severe pre-existing conditions, including Cardiogenic Shock, Heart Block greater than first degree ( 2^ nd or 3^ rd degree AV block), Overt/Uncontrolled Cardiac Failure, Severe Bradycardia (heart rate below 50 bpm), Sick Sinus Syndrome, Metabolic Acidosis, Untreated Pheochromocytoma, and Severe Peripheral Arterial Circulatory Disturbances.

Age- and Condition-Based Restrictions

Population Group Regulatory Status
Pediatric Population Not Recommended: Safety and effectiveness have not been established.
Pregnancy/Lactation Not Recommended: Associated with risks; use is restricted due to potential harm to the fetus or infant.
Renal Impairment Conditional Use: Requires mandatory dosage adjustment for patients with significant kidney function impairment.
Geriatric Patients Conditional Use: Dosage may require reduction, particularly if renal function is diminished.

Use requires caution in patients with Diabetes Mellitus or Bronchial Asthma.

What should I know about interactions with other medicines?

Panapres (pantoprazole) can interact with certain other medications, primarily due to its ability to significantly reduce stomach acid production. This change in acidity can affect how other drugs are absorbed by the body.

Reduced Absorption

Drugs that depend on stomach acid for proper absorption may have lower effectiveness when taken with Panapres. This includes certain:

  • Antifungals: Such as ketoconazole and itraconazole.
  • HIV/AIDS Medications: Including atazanavir and nelfinavir. Concurrent use is generally not recommended as it can lead to reduced drug levels and potential viral resistance.

Increased Drug Levels

While Panapres is thought to have less interaction potential than some other drugs in its class, careful monitoring is needed with:

  • Warfarin: Taking Panapres with the anticoagulant warfarin may increase the risk of bleeding due to elevated warfarin levels. International Normalized Ratio (INR) monitoring is crucial.
  • Methotrexate: High-dose methotrexate used in chemotherapy should be closely monitored with Panapres, as the interaction can increase methotrexate levels, potentially leading to toxicity.

Other Important Interactions

  • Mycophenolate Mofetil (MMF): Panapres may reduce the concentration of MMF, an immunosuppressant used to prevent organ rejection. This could reduce its effectiveness.
  • CYP2C19 Substrates: Although Panapres has a low tendency to affect the cytochrome P450 system, it is metabolized by the CYP2C19 enzyme. Medications that strongly inhibit this enzyme could potentially increase Panapres exposure.

Always inform your healthcare provider of all prescription, over-the-counter medicines, vitamins, and herbal products you are taking.

Mechanism of Action

How Panapres Works

The mechanism of action for Panapres centers on its selective influence on the H^+/ K^+- ATPase enzyme in the stomach. The drug's effects are strictly peripheral, modulating processes within the gastrointestinal system.


Targeted Inhibition of the Gastric Acid Pump

This mechanistic domain covers the drug's molecular activity: its function as an irreversible inhibitor that specifically targets the H^+/ K^+- ATPase (proton pump) in the lining of the stomach. By forming a stable, covalent bond, the drug blocks the final common step of acid production, leading to a long-duration reduction in the concentration of acid released into the stomach lumen.


Modulating the Acid Secretion Cascade

This domain addresses the resulting physiological change stemming from the molecular blockage. The drug's mechanism is only engaged when the specialized cells are actively secreting acid, allowing it to suppress signaling sequences that lead to downstream effects. This targeted pathway interference results in a modified physiological state within the stomach lining, establishing a change in the overall acid-base environment of the upper digestive tract.

Dosage and Administration Information

How to Use Panapres: Administration Guidelines

Panapres (Atenolol) usage follows specific patterns regarding administration, dosing, and scheduling. The medicine is primarily available as an oral tablet for long-term management, but an intravenous (IV) injection form is used in initial or acute hospital settings.


Dosing and Frequency Patterns

The standard approach involves starting with a low dose, such as 25 mg or 50 mg once daily. For maintenance therapy, the dose typically ranges from 50 mg to 100 mg, with 100 mg generally representing the maximum effective daily dose. Dosage adjustments, if required, are usually considered after one to two weeks, as the full effect of a change is established over this period. Tablets should be swallowed whole, and instructions may specify taking the dose before meals.


Population and Procedural Adjustments

Administration requires specific modifications for patients with impaired kidney function. For those with significantly reduced creatinine clearance (CrCl < 15 mL/min), the maximum oral dose is typically limited to 25 mg per day or 50 mg on alternate days. For older adults, the initial dose may also be reduced (25 mg once daily). Additionally, treatment must not be stopped suddenly; the dose must be gradually reduced over a period of 7 to 14 days to follow established procedural protocol.

Recent Clinical Evidence

Panapres: Recent Clinical Evidence

The clinical evaluation of Panapres (Atenolol) is documented through various types of research, including randomized controlled trials (RCTs), systematic reviews, and meta-analyses. The following overview describes what the scientific evidence has explored and what remains to be fully characterized, strictly without offering clinical guidance or interpretation.


Evidence for Use in Managing High Blood Pressure (Hypertension)

Panapres was evaluated in studies involving patient populations with high blood pressure, including older adults. Researchers applied large-scale clinical trials, monitoring outcomes related to systemic or functional imbalance such as changes in blood pressure and long-term composite cardiovascular outcomes (e.g., stroke and heart attack). Findings describe patterns observed in blood pressure readings, but long-term effects are not fully established regarding cardiovascular outcomes related to stroke compared to newer drug classes. Comparative evidence is lacking from recent large, definitive studies.


Evidence for Use in Treating Angina Pectoris (Chest Pain)

Panapres was studied for in research exploring short-term or episodic symptom patterns related to recurrent chest pain in randomized trials. Studies monitored outcomes describing episodic or acute changes, such as the frequency of symptomatic episodes and outcomes reflecting daily functioning or activity level during structured testing. Research provides insight into short-term changes, but data is limited regarding long-term, definitive cardiovascular outcomes when comparing Panapres to modern anti-anginal medications.


Evidence for Use Following a Heart Attack (Myocardial Infarction)

Panapres was studied for in patients who have experienced a recent acute heart attack. Early randomized controlled trials research examined its role during the acute phase and in the long-term observational setting. Studies monitored outcomes related to survival and the incidence of recurrent cardiac events. Much of the foundational research was conducted before the widespread use of modern cardiac interventions, meaning data for certain groups remain insufficient when applying findings to all patients receiving current, comprehensive therapeutic protocols.


What is Still Uncertain About Panapres Research

Research highlights what is known, and what is still uncertain. Major limitations include a lack of recent comparative evidence from large-scale RCTs when positioning Panapres against newer drug classes for long-term hypertension management. Furthermore, the evidence base for certain less common indications, such as specific arrhythmias, is often derived from smaller-scale or retrospective study designs; the evidence structure is diverse and does not rely on a series of large, standardized RCTs for every condition.

Key Studies & References

  1. NIH MedlinePlus: Atenolol

Frequently Asked Questions (FAQ)

Common questions about Panapres (FAQ)


Q: Is Panapres used for more than one condition?

According to official product information, Panapres is approved for use related to high blood pressure, angina (chest pain), and in a post-heart attack setting.


Q: What is the correct mechanism of action for Panapres (Atenolol)?

Panapres (atenolol) is classified as a beta1-selective adrenergic receptor antagonist, which is a cardioselective beta-blocker. This means it primarily targets and blocks beta1-receptors in the heart, an action that contributes to the reduction of cardiac strain.


Q: How quickly does Panapres typically start working?

Studies indicate that a single daily dose of Panapres is associated with a sustained reduction of blood pressure over 24 hours. The period of dose adjustment, if necessary, is typically considered after one to two weeks, as the full therapeutic effect becomes established over this time.


Q: How long do the effects of Panapres last?

Panapres is generally prescribed to be taken once daily. Official information describes the medicine as providing a sustained reduction in blood pressure over a 24-hour period.


Q: Is Panapres taken daily or only as needed?

Panapres is officially intended for long-term management of conditions like high blood pressure. For this reason, it is generally prescribed to be taken as a single daily oral dose, not on an 'as needed' basis.


Q: Is it common to feel tired when starting Panapres?

Official regulatory documents describe tiredness as a very common adverse effect when taking this medicine. Fatigue is listed as a common side effect.


Q: Is Panapres a narcotic or habit-forming drug?

The active ingredient in Panapres, atenolol, is not classified as a controlled substance under the Controlled Substances Act (CSA). Therefore, it is not considered a narcotic.


Q: What should I know about Panapres and alcohol use?

Official warnings indicate that Panapres and alcohol may have additive effects. This combination may be associated with an increased lowering of blood pressure.


Q: Can Panapres affect my ability to drive or operate machinery?

Regulatory guidance notes that the medicine may cause some people to become less alert than they are normally. Official guidance indicates that if this effect occurs, activities that require alertness, such as driving or operating machinery, may be affected.


Q: Does Panapres interact with herbal supplements?

Official guidance recommends informing a healthcare provider of all herbal remedies and supplements being taken. This is because specific information regarding interactions with herbal remedies is often limited.


Q: Can older adults (seniors) use Panapres?

Yes, Panapres can be used in older adults, but a lower initial dosage may be required. This is particularly the case if there is diminished kidney function, as regulatory information indicates the drug is mainly excreted through the kidneys.


Q: Does Panapres interact with common pain relievers like ibuprofen or Tylenol?

According to official drug interaction warnings, the long-term use (more than one week) of non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the blood pressure-lowering effect of Panapres.


Q: Is it possible for Panapres to stop working over time?

Available results from long-term studies cited in regulatory documents have not indicated any loss of antihypertensive effectiveness with prolonged use of Panapres.


Q: Does Panapres affect sleep patterns?

Sleep disturbances are listed in official regulatory documents as an uncommon adverse effect. Rare instances of nightmares have also been reported.


Q: Can Panapres cause changes in weight?

Weight gain has been listed in official regulatory documents among the rare side effects reported for the medicine.


Q: Is Panapres known to cause mood swings or depression?

Depression is described in official documents as a very common side effect. Rare instances of mood changes have also been reported.


Q: What happens when you stop taking Panapres?

Official warnings state that treatment should not be stopped abruptly. Sudden cessation may result in an increased risk of severe symptoms, which can include worsening chest pain or heart attack.


Q: Is Panapres available as a generic medicine?

Yes, the active ingredient in Panapres, atenolol, is widely available as a generic medication. The generic version has been approved by regulatory bodies under an Abbreviated New Drug Application (ANDA).


Q: How should Panapres be stored?

Panapres should be stored at room temperature, generally not above 25°C, as required by official documentation. It must be protected from moisture and heat and kept in its original, tightly closed container.


Q: How does Panapres compare to other drugs in its class?

Panapres is distinguished as a cardioselective beta-blocker. Regulatory information notes that it is water-soluble, a characteristic that may lead to different distribution and effects in the body compared to other, fat-soluble beta-blockers in its class.


Q: Can Panapres be crushed or split?

Official instructions for the tablet generally describe it as being swallowed whole. There is no explicit regulatory direction authorizing the crushing or splitting of the tablet.


Q: Does Panapres cause hair loss?

Temporary hair loss is listed in regulatory documents among the reported adverse effects where the incidence rate has not been definitively determined.


Q: Can Panapres cause problems with vision?

Official documents list vision-related effects such as blurred vision, disturbed color perception, and double vision among the reported adverse effects.


Q: Why is it important to tell my doctor about all medications I take with Panapres?

Official regulatory warnings emphasize that Panapres can interact with other prescription and non-prescription medicines. This reporting is important to prevent interactions that could affect how the drugs work or increase the risk of adverse effects.


Q: Are there any lab tests required while taking Panapres?

For patients with kidney impairment, monitoring of kidney function, specifically creatinine clearance, is described in official documents as being used to determine appropriate dosage.


Q: Does Panapres contain sugar or lactose?

Official labeling for atenolol tablets details the inactive ingredients used in the formulation. These ingredients can vary by manufacturer, and a review of specific product labels is required for full ingredient disclosure.


Q: Is a patient required to meet certain criteria to be eligible for Panapres?

Eligibility is generally defined by the approved medical conditions the drug is intended to treat. Official documents also describe criteria for ineligibility, known as contraindications, which are specific severe pre-existing conditions that prevent its use.


Q: What are the typical expected benefits of taking Panapres?

The expected benefits described in regulatory documents include a reduction in heart rate and the force of heart contractions. This action contributes to lower blood pressure and reduced strain on the heart.


Q: What is the risk of overdose with Panapres?

Regulatory documents contain information regarding overdose and list symptoms that may occur, such as severe slowing of the heart rate, very low blood pressure, and heart failure.


Q: Is Panapres safe for individuals with a history of heart problems?

Panapres is approved for use in certain heart conditions, such as high blood pressure. However, it is strictly contraindicated (must not be used) in patients with specific severe heart problems, including cardiogenic shock or heart block greater than first degree.

How should Panapres be stored and disposed of?

How to Store and Dispose of Panapres: Official Requirements

Official regulatory documents detail specific conditions required for the storage and handling of Panapres (referencing the closest regulatory analogue, Pancrex V Powder).

Storage Requirement Official Condition
Maximum Temperature Do not store above 25°C.
Sealed Shelf-Life 3 years (documented standard).
In-Use Stability If mixed with liquids or feeds, use the resulting preparation within one hour.

Handling and Disposal

The product should be kept in its original securitainer packaging. Special handling is necessary to prevent potential local irritation or allergic reactions that may occur upon contact or inhalation of the powder. Unused or expired medication should be disposed of according to general pharmaceutical waste guidelines, as no specific environmental or controlled-waste instructions are documented in the official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Panapres found in:

A-Z Index: